Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Continue

Publications

Haemodialysis, blood pressure and risk: at the limit of non-randomized evidence.

Ng SYA. et al, (2020), Nephrol Dial Transplant

In type 2 diabetes, SGLT-2 inhibitors reduce risk for major kidney outcomes.

Ai Ng SY. et al, (2020), Ann Intern Med, 172

Accelerometer-measured physical activity and functional behaviours among people on dialysis

Nawab K. et al, (2020), Clinical Kidney Journal

Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD.

Lamprea-Montealegre JA. et al, (2019), Clin J Am Soc Nephrol

Kidney disease trials for the 21st century: innovations in design and conduct.

Herrington WG. et al, (2019), Nat Rev Nephrol

Body composition and mortality from vascular or metabolic causes among 150,000 participants in the Mexico City Prospective Study

Gnatiuc L. et al, (2019), EUROPEAN HEART JOURNAL, 40, 2412 - 2412

General and Abdominal Adiposity and Mortality in Mexico City: Prospective Study of 150 000 Adults.

Gnatiuc L. et al, (2019), Ann Intern Med

Chronic kidney disease, heart failure and neprilysin inhibition.

Haynes R. et al, (2019), Nephrol Dial Transplant

Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.

Schlackow I. et al, (2019), Kidney Int

In high-risk T2DM, canagliflozin reduced CV events regardless of baseline renal function.

Herrington WG. et al, (2019), Ann Intern Med, 170

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials.

Cholesterol Treatment Trialists' Collaboration None., (2019), Lancet, 393, 407 - 415

Feasibility of Telemonitoring Blood Pressure in Patients With Kidney Disease (Oxford Heart and Renal Protection Study-1): Observational Study.

Warner BE. et al, (2018), JMIR Cardio, 2

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.

Herrington WG. et al, (2018), Clin Kidney J, 11, 749 - 761

Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease.

Haynes R. et al, (2018), Circulation, 138, 1505 - 1514

Authors' Reply.

Herrington WG. et al, (2018), J Am Soc Nephrol, 29, 2602 - 2603

Adiposity and vascular-metabolic mortality among 150,000 Mexican adults followed for 15 years

GNATIUC L. et al, (2018)

Change in Albuminuria and Risk of Renal and Cardiovascular Outcomes: Natural Variation Should Be Taken into Account.

Smith M. et al, (2018), Kidney Int Rep, 3, 939 - 949

Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis.

Marthi A. et al, (2018), J Am Soc Nephrol, 29, 2015 - 2027

Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980 793 adults from 68 prospective studies.

Prospective Studies Collaboration and Asia Pacific Cohort Studies Collaboration None., (2018), Lancet Diabetes Endocrinol, 6, 538 - 546

Cardiovascular Outcomes Reported in Hemodialysis Trials

O'Lone E. et al, (2018), Journal of the American College of Cardiology, 71, 2802 - 2810

Load More

1
2
3
4
5

Include forthcoming?